Exacis Biotherapeutics Presents Data On Its Stealth mRNA-engineered NK-cell Platform At American Society Of Gene & Cell Therapy Annual Meeting

By |2021-07-02T19:46:24+00:00May 25th, 2021|

Exacis produces its iPSC-derived ExaNK™ cells using its proprietary mRNA-based cell reprogramming and gene editing technologies